Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Versus Delayed Administration.
Anticancer Res
; 38(10): 5877-5881, 2018 10.
Article
em En
| MEDLINE
| ID: mdl-30275213
ABSTRACT
BACKGROUND/AIM:
In patients with recurrent glioblastoma, the best timing to administer bevacizumab is not well addressed yet. In this study, we reported the results of a monocentric experience comparing the early use of bevacizumab (following the first GBM recurrence) with the delayed administration (following the second or even further GBM recurrences). MATERIALS ANDMETHODS:
This analysis included 129 glioblastoma patients with a median follow-up of 22.4 months (range=5.26-192 months).RESULTS:
The median time lapse from diagnosis of glioblastoma to disease recurrence was 11.6 months; 13.1 for patients treated with deferred administration of bevacizumab and 9.9 for patients with early administration (p=0.047). Bevacizumab progression-free survival with early and delayed use was 3.45 and 2.92 months, respectively (p=0.504). Survival time from the start of bevacizumab was 6.18 months in patients with early administration, and 6.47 in the delayed administration one (p=0.318).CONCLUSION:
Delayed administration of bevacizumab can be considered in selected patients with less aggressive recurrent glioblastoma.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Glioblastoma
/
Inibidores da Angiogênese
/
Bevacizumab
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2018
Tipo de documento:
Article